DiscoveRx Corporation Signs Agreement with Cosmo Bio
News Feb 07, 2008
DiscoveRx Corporation announces the selection of Cosmo Bio Co., Ltd. as a key distributor for the Japanese territory.
“Cosmo Bio's leadership in providing third party drug discovery services to the Japanese pharmaceutical and biotech industries and in the distribution of products for life science research is well recognized throughout Japan. We believe that the addition of DiscoveRx Corporation’s Selectivity Screen™ GPCR profiling services will significantly benefit Cosmo Bio’s customers,” said Theresa Schaub, Director, Drug Discovery Screening Services at DiscoveRx.
Dr. Haruhisa Sakurai, Director of Cosmo Bio’s Drug Discovery Services team, remarked, “Many drugs relate to their effects via a family of proteins called G-protein-coupled receptors (GPCR). Many industries have focused the development of drugs as one of important targets. To accelerate discovery of more selective screening for disease, we are very excited by the opportunity to offer GPCR Profiling Service by DiscoveRx to Japanese customers.”
Additionally, DiscoveRx Corporation continues to add targets to its discovery service offering. The recent introduction of Nuclear Hormone Receptors, Kinases and Orphan GPCRs complement DiscoveRx Corporation’s PathHunter™ Cell Based Assays, HitHunter™ Biochemical Assays and screening reagents. Global adoption of the PathHunter™ EFC technology has contributed to discovery of compounds worldwide.
Using Epigenetic Signatures and Machine Learning to Improve DiagnosisNews
Unique epigenetic signatures for nine neurodevelopmental disorders have been identified, lending to a better method of diagnosis for disorders with much clinical overlap.READ MORE
Extra-Resistant Wheat is Created From New Gene CombinationNews
A new combination of different strains of resistant wheat may help farmers avoid a common fungal disease.READ MORE